Skip to main content Accessibility help
×
×
Home

Immunopsychiatry: important facts

  • G. M. Khandaker (a1) (a2), R. Dantzer (a3) and P. B. Jones (a1) (a2)

Abstract

Accumulating evidence indicate a role for the immune system particularly inflammation and autoimmunity in the aetiology of major psychiatric disorders such as depression and schizophrenia. In this paper, we discuss some of the key advances in immunopsychiatry in order to highlight to psychiatrists and other health professionals how an increased understanding of this field might enhance our knowledge of illness mechanism and approaches to treatment. We present a brief overview of clinical research that link inflammation and autoimmunity with depression and psychosis, including potential role of inflammation in treatment response, current evidence for the effectiveness of immune-modulating treatment for depression and psychosis, and possible role of inflammation in common physical comorbidities for these disorders such as coronary heart disease and diabetes mellitus. Gaining a better understanding of the role of immune system could be paradigm changing for psychiatry. We need collaborations between clinicians and scientists to deliver high-quality translational research in order to fully realise the clinical potential of this exciting and rapidly expanding field.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Immunopsychiatry: important facts
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Immunopsychiatry: important facts
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Immunopsychiatry: important facts
      Available formats
      ×

Copyright

This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.

Corresponding author

*Address for correspondence: Dr G. M. Khandaker, Department of Psychiatry, University of Cambridge, Box 189, Cambridge Biomedical Campus, Cambridge CB2 0QQ, UK. (Email: gmk24@medschl.cam.ac.uk)

References

Hide All
Abel, KM, Wicks, S, Susser, ES, Dalman, C, Pedersen, MG, Mortensen, PB, Webb, RT (2010). Birth weight, schizophrenia, and adult mental disorder: is risk confined to the smallest babies? Archives of General Psychiatry 67, 923930.
Barker, DJ, Gluckman, PD, Godfrey, KM, Harding, JE, Owens, JA, Robinson, JS (1993 a). Fetal nutrition and cardiovascular disease in adult life. Lancet 341, 938941.
Barker, DJ, Hales, CN, Fall, CH, Osmond, C, Phipps, K, Clark, PM (1993 b). Type 2 (non-insulin-dependent) diabetes mellitus, hypertension and hyperlipidaemia (syndrome X): relation to reduced fetal growth. Diabetologia 36, 6267.
Baumeister, D, Akhtar, R, Ciufolini, S, Pariante, CM, Mondelli, V (2016). Childhood trauma and adulthood inflammation: a meta-analysis of peripheral C-reactive protein, interleukin-6 and tumour necrosis factor-alpha. Molecular Psychiatry 21, 642649.
Benros, ME, Nielsen, PR, Nordentoft, M, Eaton, WW, Dalton, SO, Mortensen, PB (2011). Autoimmune diseases and severe infections as risk factors for schizophrenia: a 30-year population-based register study. American Journal of Psychiatry 168, 13031310.
Bloomfield, PS, Selvaraj, S, Veronese, M, Rizzo, G, Bertoldo, A, Owen, DR, Bloomfield, MA, Bonoldi, I, Kalk, N, Turkheimer, F, McGuire, P, de Paola, V, Howes, OD (2016). Microglial activity in people at ultra high risk of psychosis and in schizophrenia: an [(11)C]PBR28 PET brain imaging study. American Journal of Psychiatry 173, 4452.
Bonaccorso, S, Marino, V, Biondi, M, Grimaldi, F, Ippoliti, F, Maes, M (2002). Depression induced by treatment with interferon-alpha in patients affected by hepatitis C virus. Journal of Affective Disorders 72, 237241.
Brown, AS, Derkits, EJ (2010). Prenatal infection and schizophrenia: a review of epidemiologic and translational studies. American Journal of Psychiatry 167, 261280.
Brown, AS, Sourander, A, Hinkka-Yli-Salomaki, S, McKeague, IW, Sundvall, J, Surcel, HM (2014). Elevated maternal C-reactive protein and autism in a national birth cohort. Molecular Psychiatry 19, 259264.
Capuron, L, Gumnick, JF, Musselman, DL, Lawson, DH, Reemsnyder, A, Nemeroff, CB, Miller, AH (2002). Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 26, 643652.
Carlsson, M, Carlsson, A (1990). Schizophrenia: a subcortical neurotransmitter imbalance syndrome? Schizophrenia Bulletin 16, 425432.
Carvalho, LA, Torre, JP, Papadopoulos, AS, Poon, L, Juruena, MF, Markopoulou, K, Cleare, AJ, Pariante, CM (2013). Lack of clinical therapeutic benefit of antidepressants is associated overall activation of the inflammatory system. Journal of Affective Disorders 148, 136140.
Chaudhry, IB, Hallak, J, Husain, N, Minhas, F, Stirling, J, Richardson, P, Dursun, S, Dunn, G, Deakin, B (2012). Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment. Journal of Psychopharmacology 26, 11851193.
Christmas, DM, Potokar, J, Davies, SJ (2011). A biological pathway linking inflammation and depression: activation of indoleamine 2,3-dioxygenase. Neuropsychiatric Disease and Treatment 7, 431439.
Danese, A, Moffitt, TE, Pariante, CM, Ambler, A, Poulton, R, Caspi, A (2008). Elevated inflammation levels in depressed adults with a history of childhood maltreatment. Archives of General Psychiatry 65, 409415.
Danesh, J, Wheeler, JG, Hirschfield, GM, Eda, S, Eiriksdottir, G, Rumley, A, Lowe, GD, Pepys, MB, Gudnason, V (2004). C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. New England Journal of Medicine 350, 13871397.
Dantzer, R, O'Connor, JC, Freund, GG, Johnson, RW, Kelley, KW (2008). From inflammation to sickness and depression: when the immune system subjugates the brain. Nature Reviews Neuroscience 9, 4656.
de Witte, LD, Hoffmann, C, van Mierlo, HC, Titulaer, MJ, Kahn, RS, Martinez-Martinez, P, D European Consortium of Autoimmune Mental (2015). Absence of N-Methyl-D-aspartate receptor IgG autoantibodies in schizophrenia: the importance of cross-validation studies. JAMA Psychiatry 72, 731733.
Dickens, C, Creed, F (2001). The burden of depression in patients with rheumatoid arthritis. Rheumatology (Oxford) 40, 13271330.
Doorduin, J, de Vries, EF, Willemsen, AT, de Groot, JC, Dierckx, RA, Klein, HC (2009). Neuroinflammation in schizophrenia-related psychosis: a PET study. Journal of Nuclear Medicine 50, 18011807.
Eaton, WW, Byrne, M, Ewald, H, Mors, O, Chen, CY, Agerbo, E, Mortensen, PB (2006). Association of schizophrenia and autoimmune diseases: linkage of Danish national registers. American Journal of Psychiatry 163, 521528.
Eraly, SA, Nievergelt, CM, Maihofer, AX, Barkauskas, DA, Biswas, N, Agorastos, A, O'Connor, DT, Baker, DG, T Marine Resiliency Study (2014). Assessment of plasma C-reactive protein as a biomarker of posttraumatic stress disorder risk. JAMA Psychiatry 71, 423431.
Erhardt, S, Blennow, K, Nordin, C, Skogh, E, Lindstrom, LH, Engberg, G (2001). Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia. Neuroscience Letters 313, 9698.
Garver, DL, Tamas, RL, Holcomb, JA (2003). Elevated interleukin-6 in the cerebrospinal fluid of a previously delineated schizophrenia subtype. Neuropsychopharmacology 28, 15151520.
Gimeno, D, Kivimaki, M, Brunner, EJ, Elovainio, M, De Vogli, R, Steptoe, A, Kumari, M, Lowe, GD, Rumley, A, Marmot, MG, Ferrie, JE (2009). Associations of C-reactive protein and interleukin-6 with cognitive symptoms of depression: 12-year follow-up of the Whitehall II study. Psychological Medicine 39, 413423.
Goldsmith, DR, Rapaport, MH, Miller, BJ (2016). A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression. Molecular Psychiatry 21, 16961709.
Haapakoski, R, Mathieu, J, Ebmeier, KP, Alenius, H, Kivimaki, M (2015). Cumulative meta-analysis of interleukins 6 and 1beta, tumour necrosis factor alpha and C-reactive protein in patients with major depressive disorder. Brain Behaviour and Immunity 49, 206215.
Haroon, E, Raison, CL, Miller, AH (2012). Psychoneuroimmunology meets neuropsychopharmacology: translational implications of the impact of inflammation on behavior. Neuropsychopharmacology 37, 137162.
Harrison, NA, Brydon, L, Walker, C, Gray, MA, Steptoe, A, Critchley, HD (2009). Inflammation causes mood changes through alterations in subgenual cingulate activity and mesolimbic connectivity. Biological Psychiatry 66, 407414.
Hodes, GE, Pfau, ML, Leboeuf, M, Golden, SA, Christoffel, DJ, Bregman, D, Rebusi, N, Heshmati, M, Aleyasin, H, Warren, BL, Lebonte, B, Horn, S, Lapidus, KA, Stelzhammer, V, Wong, EH, Bahn, S, Krishnan, V, Bolanos-Guzman, CA, Murrough, JW, Merad, M, Russo, SJ (2014). Individual differences in the peripheral immune system promote resilience versus susceptibility to social stress. Proceedings of the National Academy of Sciences of the United States of America 111, 1613616141.
Howren, MB, Lamkin, DM, Suls, J (2009). Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosomatic Medicine 71, 171186.
Jokela, M, Virtanen, M, Batty, GD, Kivimaki, M (2016). Inflammation and specific symptoms of depression. JAMA Psychiatry 73, 8788.
Kappelmann, N, Lewis, G, Dantzer, R, Jones, PB, Khandaker, GM (2016). Antidepressant activity of anti-cytokine treatment: a systematic review and meta-analysis of clinical trials of chronic inflammatory conditions. Molecular Psychiatry. doi: 10.1038/mp.2016.167. [Epub ahead of print].
Khandaker, GM, Cousins, L, Deakin, J, Lennox, BR, Yolken, R, Jones, PB (2015). Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment. The Lancet Psychiatry 2, 258270.
Khandaker, GM, Dantzer, R (2016). Is there a role for immune-to-brain communication in schizophrenia? Psychopharmacology (Berlin) 233, 15591573.
Khandaker, GM, Pearson, RM, Zammit, S, Lewis, G, Jones, PB (2014 a). Association of serum interleukin 6 and C-reactive protein in childhood with depression and psychosis in young adult life: a population-based longitudinal study. JAMA Psychiatry 71, 11211128.
Khandaker, GM, Zammit, S, Lewis, G, Jones, PB (2014 b). A population-based study of atopic disorders and inflammatory markers in childhood before psychotic experiences in adolescence. Schizophrenia Research 152, 139145.
Khandaker, GM, Zammit, S, Lewis, G, Jones, PB (2016). Association between serum C-reactive protein and DSM-IV generalized anxiety disorder in adolescence: findings from the ALSPAC cohort. Neurobiology of Stress 4, 5561.
Khandaker, GM, Zimbron, J, Dalman, C, Lewis, G, Jones, PB (2012). Childhood infection and adult schizophrenia: a meta-analysis of population-based studies. Schizophrenia Research 139, 161168.
Khandaker, GM, Zimbron, J, Lewis, G, Jones, PB (2013). Prenatal maternal infection, neurodevelopment and adult schizophrenia: a systematic review of population-based studies. Psychological Medicine 43, 239257.
Kohler, O, Benros, ME, Nordentoft, M, Farkouh, ME, Iyengar, RL, Mors, O, Krogh, J (2014). Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry 71, 13811391.
Lachance, LR, McKenzie, K (2014). Biomarkers of gluten sensitivity in patients with non-affective psychosis: a meta-analysis. Schizophrenia Research 152, 521527.
Maes, M, Bosmans, E, De Jongh, R, Kenis, G, Vandoolaeghe, E, Neels, H (1997). Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. Cytokine 9, 853858.
Maes, M, Meltzer, HY, Bosmans, E (1994). Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine. Acta Psychiatrica Scandinavica 89, 346351.
Metcalf, SA, Jones, PB, Nordstrom, T, Timonen, M, Maki, P, Miettunen, J, Jaaskelainen, E, Jarvelin, MR, Stochl, J, Murray, GK, Veijola, J, Khandaker, GM (2017). Serum C-reactive protein in adolescence and risk of schizophrenia in adulthood: a prospective birth cohort study. Brain Behaviour and Immunity 59, 253259.
Miller, BJ, Buckley, P, Seabolt, W, Mellor, A, Kirkpatrick, B (2011). Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biological Psychiatry 70, 663671.
Miller, BJ, Dias, JK, Lemos, HP, Buckley, PF (2016). An open-label, pilot trial of adjunctive tocilizumab in schizophrenia. Journal of Clinical Psychiatry 77, 275276.
Mondelli, V, Ciufolini, S, Belvederi Murri, M, Bonaccorso, S, Di Forti, M, Giordano, A, Marques, TR, Zunszain, PA, Morgan, C, Murray, RM, Pariante, CM, Dazzan, P (2015). Cortisol and inflammatory biomarkers predict poor treatment response in first episode psychosis. Schizophrenia Bulletin 41, 11621170.
Mukherjee, D, Nissen, SE, Topol, EJ (2001). Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 286, 954959.
Muller, N, Riedel, M, Scheppach, C, Brandstatter, B, Sokullu, S, Krampe, K, Ulmschneider, M, Engel, RR, Moller, HJ, Schwarz, MJ (2002). Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. American Journal of Psychiatry 159, 10291034.
Nemeroff, CB (2007). Prevalence and management of treatment-resistant depression. Journal of Clinical Psychiatry 68(Suppl 8), 1725.
Nikkheslat, N, Zunszain, PA, Horowitz, MA, Barbosa, IG, Parker, JA, Myint, AM, Schwarz, MJ, Tylee, AT, Carvalho, LA, Pariante, CM (2015). Insufficient glucocorticoid signaling and elevated inflammation in coronary heart disease patients with comorbid depression. Brain Behaviour and Immunity 48, 818.
O'Brien, SM, Scully, P, Fitzgerald, P, Scott, LV, Dinan, TG (2007). Plasma cytokine profiles in depressed patients who fail to respond to selective serotonin reuptake inhibitor therapy. Journal of Psychiatric Research 41, 326331.
O'Connor, JC, Lawson, MA, Andre, C, Moreau, M, Lestage, J, Castanon, N, Kelley, KW, Dantzer, R (2009). Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice. Molecular Psychiatry 14, 511522.
Pearlman, DM, Najjar, S (2014). Meta-analysis of the association between N-methyl-d-aspartate receptor antibodies and schizophrenia, schizoaffective disorder, bipolar disorder, and major depressive disorder. Schizophrenia Research 157, 249258.
Pedersen, MS, Benros, ME, Agerbo, E, Borglum, AD, Mortensen, PB (2012). Schizophrenia in patients with atopic disorders with particular emphasis on asthma: a Danish population-based study. Schizophrenia Research 138, 5862.
Pollak, TA, McCormack, R, Peakman, M, Nicholson, TR, David, AS (2014). Prevalence of anti-N-methyl-D-aspartate (NMDA) receptor [corrected] antibodies in patients with schizophrenia and related psychoses: a systematic review and meta-analysis. Psychological Medicine 44, 24752487.
Pradhan, AD, Manson, JE, Rifai, N, Buring, JE, Ridker, PM (2001). C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 286, 327334.
Raison, CL, Capuron, L, Miller, AH (2006). Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends in Immunology 27, 2431.
Raison, CL, Rutherford, RE, Woolwine, BJ, Shuo, C, Schettler, P, Drake, DF, Haroon, E, Miller, AH (2013). A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry 70, 3141.
Rossi, S, Sacchetti, L, Napolitano, F, De Chiara, V, Motta, C, Studer, V, Musella, A, Barbieri, F, Bari, M, Bernardi, G, Maccarrone, M, Usiello, A, Centonze, D (2012). Interleukin-1beta causes anxiety by interacting with the endocannabinoid system. Journal of Neuroscience 32, 1389613905.
Schizophrenia Working Group of the Psychiatric Genomics (2014). Biological insights from 108 schizophrenia-associated genetic loci. Nature 511, 421427.
Schmidt, R, Schmidt, H, Curb, JD, Masaki, K, White, LR, Launer, LJ (2002). Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia Aging Study. Annals of Neurology 52, 168174.
Schwarcz, R, Pellicciari, R (2002). Manipulation of brain kynurenines: glial targets, neuronal effects, and clinical opportunities. Journal of Pharmacology and Experimental Therapeutics 303, 110.
Schwarcz, R, Rassoulpour, A, Wu, HQ, Medoff, D, Tamminga, CA, Roberts, RC (2001). Increased cortical kynurenate content in schizophrenia. Biological Psychiatry 50, 521530.
Sekar, A, Bialas, AR, de Rivera, H, Davis, A, Hammond, TR, Kamitaki, N, Tooley, K, Presumey, J, Baum, M, Van Doren, V, Genovese, G, Rose, SA, Handsaker, RE, Daly, MJ, Carroll, MC, Stevens, B, McCarroll, SA, C Schizophrenia Working Group of the Psychiatric Genomics (2016). Schizophrenia risk from complex variation of complement component 4. Nature 530, 177183.
Sommer, IE, van Westrhenen, R, Begemann, MJ, de Witte, LD, Leucht, S, Kahn, RS (2014). Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update. Schizophrenia Bulletin 40, 181191.
Steiner, J, Walter, M, Glanz, W, Sarnyai, Z, Bernstein, HG, Vielhaber, S, Kastner, A, Skalej, M, Jordan, W, Schiltz, K, Klingbeil, C, Wandinger, KP, Bogerts, B, Stoecker, W (2013). Increased prevalence of diverse N-methyl-D-aspartate glutamate receptor antibodies in patients with an initial diagnosis of schizophrenia: specific relevance of IgG NR1a antibodies for distinction from N-methyl-D-aspartate glutamate receptor encephalitis. JAMA Psychiatry 70, 271278.
Tzoulaki, I, Jarvelin, MR, Hartikainen, AL, Leinonen, M, Pouta, A, Paldanius, M, Ruokonen, A, Canoy, D, Sovio, U, Saikku, P, Elliott, P (2008). Size at birth, weight gain over the life course, and low-grade inflammation in young adulthood: Northern Finland 1966 Birth Cohort study. European Heart Journal 29, 10491056.
Upthegrove, R, Manzanares-Teson, N, Barnes, NM (2014). Cytokine function in medication-naive first episode psychosis: a systematic review and meta-analysis. Schizophrenia Research 155, 101108.
Wium-Andersen, MK, Orsted, DD, Nielsen, SF, Nordestgaard, BG (2013). Elevated C-reactive protein levels, psychological distress, and depression in 73, 131 individuals. JAMA Psychiatry 70, 176184.
Zalli, A, Jovanova, O, Hoogendijk, WJ, Tiemeier, H, Carvalho, LA (2016). Low-grade inflammation predicts persistence of depressive symptoms. Psychopharmacology (Berlin) 233, 16691678.
Zandi, MS, Deakin, JB, Morris, K, Buckley, C, Jacobson, L, Scoriels, L, Cox, AL, Coles, AJ, Jones, PB, Vincent, A, Lennox, BR (2014). Immunotherapy for patients with acute psychosis and serum N-methyl d-aspartate receptor (NMDAR) antibodies: a description of a treated case series. Schizophrenia Research 160, 193195.
Zandi, MS, Irani, SR, Lang, B, Waters, P, Jones, PB, McKenna, P, Coles, AJ, Vincent, A, Lennox, BR (2011). Disease-relevant autoantibodies in first episode schizophrenia. Journal of Neurology 258, 686688.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Psychological Medicine
  • ISSN: 0033-2917
  • EISSN: 1469-8978
  • URL: /core/journals/psychological-medicine
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Keywords

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed